UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

D Systems Corporation (NYSE:DDD) announced today its financial results for the second quarter ended June 30, 2025. Revenue of $95 million led by double-digit ...

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

Galvanize Therapeutics begins patient enrolment in PROPEL Registry evaluating Aliya PEF Ablation for soft tissue lesions: Redwood City, California Monday, August 18, 2025, 12:00 H ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

As the Dow Jones Industrial Average reaches an all-time high, investors are keenly watching for opportunities amid mixed performances in major indices. In this context, penny stocks—often representing ...

DelveInsight projects strong NMOSD market growth in the 7MM through 2032, fueled by disease-modifying therapies and key ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call.

As RL-007 progresses through late-stage clinical development, it represents a significant advancement in schizophrenia ...